glp 1 agonist australia Clinical Practice Recommendation On Periprocedural Use Of GLP-1/GIP Receptor Agonists (June 2024) GLP-1 Agonists: A Comprehensive Overview
Description
2025, doi: 10.14309/ajg.0000000000003760
Tirzepatide came off the FDAs official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs
There was a non-significant decreased risk of CRC when compared with alpha-glucosidase or DPP-4i
A Kaiser Family Foundation (KFF) analysis found that Affordable Care Act Marketplace plans rarely cover GLP-1s approved for obesity treatment
Understanding the specific dose you are using helps calibrate expectations for both benefits and side effects
Semaglutide is associated with increased neoplasm and tumorigenesis, specifically in the thyroid, bladder, colorectal, and pancreas
